Bison Wealth LLC Sells 907 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Bison Wealth LLC lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 16.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,622 shares of the company’s stock after selling 907 shares during the quarter. Bison Wealth LLC’s holdings in TransMedics Group were worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Executive Wealth Management LLC raised its stake in TransMedics Group by 32.7% in the fourth quarter. Executive Wealth Management LLC now owns 28,141 shares of the company’s stock valued at $2,221,000 after purchasing an additional 6,928 shares in the last quarter. Moody Aldrich Partners LLC increased its holdings in shares of TransMedics Group by 110.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after buying an additional 24,290 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of TransMedics Group during the 4th quarter valued at $684,000. Abundance Wealth Counselors bought a new stake in shares of TransMedics Group during the 4th quarter worth $390,000. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in shares of TransMedics Group by 47.0% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 17,252 shares of the company’s stock worth $1,362,000 after acquiring an additional 5,515 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $93.31 on Wednesday. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $99.63. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock’s 50-day moving average price is $83.01 and its 200-day moving average price is $72.77.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. During the same period in the previous year, the firm earned ($0.21) EPS. The business’s quarterly revenue was up 158.6% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on TMDX. Oppenheimer increased their target price on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Morgan Stanley raised their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Piper Sandler started coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

Insider Buying and Selling

In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $74.01, for a total transaction of $1,110,150.00. Following the completion of the sale, the chief financial officer now owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $74.01, for a total transaction of $1,110,150.00. Following the completion of the transaction, the chief financial officer now owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 2,330 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total value of $209,909.70. Following the completion of the sale, the insider now owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. Insiders have sold a total of 115,408 shares of company stock valued at $9,802,401 over the last three months. 6.70% of the stock is owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.